Lupus drug continuation trial offers hope for disease control
NCT ID NCT06875960
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being enrolled, all of whom have already shown benefit from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Local Institution - 0001
WITHDRAWNFarmington, Connecticut, 06030, United States
-
Local Institution - 0003
WITHDRAWNJackson, Tennessee, 38305, United States
-
New York University School Of Medicine
RECRUITINGNew York, New York, 10155, United States
Contact Phone: •••-•••-••••
-
Oklahoma Medical Research Foundation
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deucravacitinib
What this could lead to
If successful, this could provide a long-term treatment option to control lupus symptoms and reduce flare-ups.
What could go wrong
This is a small continuation study with only 35 participants, so results may not apply to all lupus patients. Risks include potential side effects from long-term use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.